CFDE Data Portal | Search MARS1

	Label	Description
	MARS1 Gene (Entity type)	ENSG00000166986 - methionyl-tRNA synthetase 1
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

MARS1

ENSG00000166986 - methionyl-tRNA synthetase 1

GSE120612 etoposide leukocyte 6 v 1 human up

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.